Sphingolipid Metabolism in Neurodegeneration

Migration, Crosslink

📖

Sphingolipid Metabolism in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:49 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-sphingolipid-metabolism-

📖 Wiki Page

mechanisms3241 wordssynced 2026-04-02

Sphingolipid Metabolism in Neurodegeneration

Sphingolipid metabolism is a critical biochemical pathway that has emerged as a significant contributor to neurodegenerative disease pathogenesis. The sphingolipid pathway regulates essential cellular processes including membrane structure, cell signaling, [apoptosis](/entities/apoptosis), and neuroinflammation. Dysregulation of sphingolipid homeostasis has been documented in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple other neurodegenerative conditions.

Overview of Sphingolipid Metabolism

Sphingolipids are a class of lipids containing a sphingoid base backbone (typically sphingosine). Unlike glycerophospholipids, sphingolipids are built around a ceramide backbone, making them uniquely positioned to serve both structural and signaling functions[@hannun2008]. The sphingolipid metabolic network encompasses multiple branches that converge on key bioactive intermediates, particularly ceramide and sphingosine-1-phosphate (S1P), which have opposing roles in determining cell fate.

Key Intermediates and Their Functions

...

Sphingolipid Metabolism in Neurodegeneration

Sphingolipid metabolism is a critical biochemical pathway that has emerged as a significant contributor to neurodegenerative disease pathogenesis. The sphingolipid pathway regulates essential cellular processes including membrane structure, cell signaling, [apoptosis](/entities/apoptosis), and neuroinflammation. Dysregulation of sphingolipid homeostasis has been documented in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple other neurodegenerative conditions.

Overview of Sphingolipid Metabolism

Sphingolipids are a class of lipids containing a sphingoid base backbone (typically sphingosine). Unlike glycerophospholipids, sphingolipids are built around a ceramide backbone, making them uniquely positioned to serve both structural and signaling functions[@hannun2008]. The sphingolipid metabolic network encompasses multiple branches that converge on key bioactive intermediates, particularly ceramide and sphingosine-1-phosphate (S1P), which have opposing roles in determining cell fate.

Key Intermediates and Their Functions

Ceramide serves as the central hub of sphingolipid metabolism. Synthesized through three distinct pathways—de novo synthesis, salvage pathway, and sphingomyelin hydrolysis—ceramide acts as both a structural component of cell membranes and a potent bioactive messenger[@goi2009]. Elevated ceramide levels promote apoptosis through mitochondrial dysfunction, caspase activation, and ER stress, while also modulating inflammation through NF-κB signaling.

Sphingosine-1-phosphate (S1P) represents the counterbalancing metabolite in the "sphingolipid rheostat" concept. Generated by phosphorylation of sphingosine via sphingosine kinase (SK1 and SK2), S1P binds to a family of five G-protein-coupled receptors (S1PR1-5) to promote cell survival, proliferation, and anti-inflammatory responses[@maceyka2012]. The balance between ceramide (pro-apoptotic) and S1P (pro-survival) fundamentally influences neuronal fate in neurodegeneration.

Glycosphingolipids, including gangliosides (GM1, GM2, GM3, GD1a, GD1b, GT1b), are highly enriched in neuronal membranes, particularly at synapses. These complex lipids regulate neurotransmitter receptor trafficking, axon guidance, and calcium homeostasis. Alterations in ganglioside composition are early events in AD pathogenesis[@aureli2015].

Key Enzymes in Sphingolipid Metabolism

| Enzyme | Gene | Function | Disease Relevance |
|--------|------|----------|------------------|
| Serine Palmitoyltransferase (SPT) | SPTLC1, SPTLC2 | First step in de novo ceramide synthesis | ALS, HSAN1 |
| Ceramide Synthase (CerS) | CERS1-6 | Acyl-CoA-dependent ceramide synthesis | AD, PD |
| Ceramidase | ASAH1, ASAH2 | Converts ceramide to sphingosine | PD, Farber disease |
| Sphingosine Kinase (SK) | SPHK1, SPHK2 | Produces S1P | Neuroprotection |
| Glucocerebrosidase (GCase) | GBA | Catabolizes glucosylceramide | PD, Gaucher disease |
| Acid Sphingomyelinase (ASM) | SMPD1 | Breaks down sphingomyelin | NPD, AD |
| Neutral Sphingomyelinase (NSM) | SMPD2, SMPD3 | Generates ceramide | Inflammation |

Molecular Mechanisms in Neurodegeneration

Ceramide-Mediated Apoptosis

Ceramide accumulation triggers neuronal apoptosis through multiple interconnected pathways[@obeid2000]:

Mitochondrial dysfunction: Ceramide directly permeabilizes mitochondrial outer membrane, releasing cytochrome c and activating caspase-9/caspase-3 cascade. This process involves oligomerization of pro-apoptotic proteins BAX and BAK, creating pores in the mitochondrial outer membrane[@dbaibo2009].

ER stress: Ceramide activates the unfolded protein response through PERK and IRE1α signaling. Chronic ER stress leads to CHOP-mediated pro-apoptotic transcription and protein synthesis inhibition[@szegezdi2006].

Calpain activation: Ceramide-induced calpain activation degrades cytoskeletal proteins and ion channels, contributing to cytoskeletal disruption and calcium dysregulation[@wang2000].

Autophagy dysregulation: Ceramide inhibits mTOR signaling, leading to excessive autophagic flux that can result in autophagic cell death. The dual role of ceramide in autophagy makes its net effect context-dependent[@scarlatti2008].

NF-κB signaling: Ceramide can activate both pro-survival and pro-inflammatory NF-κB pathways, creating complex downstream effects that vary by cell type and disease context.

The selective vulnerability of [dopaminergic neurons](/cell-types/dopaminergic-neurons) in PD correlates with their heightened sensitivity to ceramide-induced apoptosis[@garciagonzalez2023]. Studies show that substantia nigra pars compacta neurons have lower antioxidant defenses and higher basal ceramide levels compared to other brain regions, making them particularly susceptible to ceramide-mediated cell death.

Sphingosine-1-Phosphate Signaling

S1P receptor signaling exerts complex effects on neuronal survival through five G-protein-coupled receptors with distinct expression patterns and signaling cascades[@strub2010]:

S1PR1: Couples to Gi/o proteins, promoting PI3K/Akt and Rac GTPase signaling. Promotes oligodendrocyte survival and myelination; dysregulated in multiple sclerosis[@cohen2016]
S1PR2: Couples to Gi/o, Gq, and G12/13, activating Rho GTPases. Mediates astrocyte reactivity and neuroinflammation through NF-κB activation
S1PR3: Similar to S1PR2 with additional cAMP modulation. Involved in neurovascular unit homeostasis
S1PR4: Primarily G12/13 coupled, regulating immune cell trafficking and cytokine production
S1PR5: Highly expressed in oligodendrocytes and NK cells. Critical for oligodendrocyte progenitor cell migration

Fingolimod (FTY720), a pan-S1PR modulator, cross-reacts with S1PR1, 3, 4, and 5 after phosphorylation in vivo, making its CNS effects complex and context-dependent[@brinkmann2002]. The drug was the first oral therapy approved for multiple sclerosis, demonstrating the therapeutic potential of sphingolipid pathway modulation.

Ganglioside-Alpha-Synuclein Interaction

The interaction between gangliosides and [alpha-synuclein](/proteins/alpha-synuclein) represents a critical nexus in PD pathogenesis[@martinez2023]. GM1 and GM3 gangliosides bind directly to alpha-synuclein, modulating its aggregation kinetics through multiple mechanisms:

GM1 binding: Stabilizes alpha-synuclein in an α-helical conformation, initially protective against aggregation. However, at high concentrations, GM1 can also promote the formation of toxic oligomers[@martinez2007]
GM3 interaction: Promotes aggregation at high concentrations through charge-neutralization effects on the N-terminal region of alpha-synuclein
Membrane microdomains: Lipid rafts concentrate alpha-synuclein and gangliosides, facilitating nucleation and aggregation. The pre-formed alpha-synuclein seeds can then propagate to neighboring cells[@deshpande2020]
Cell-to-cell transmission: Ganglioside-containing exosomes and membrane fragments facilitate the spread of alpha-synuclein pathology

Role in Alzheimer's Disease

In Alzheimer's disease, sphingolipid metabolism is significantly altered at multiple levels. Post-mortem studies consistently demonstrate elevated ceramide levels in AD brain tissue, with increases ranging from 50-300% depending on brain region and disease stage[@cutler2004].

Ceramide Accumulation and Amyloid Pathology

The relationship between ceramide and amyloid-beta ([Aβ](/proteins/amyloid-beta)) is bidirectional, creating a vicious cycle that drives disease progression[@jana2010]:

Aβ stimulates ceramide synthesis: Amyloid-beta activates serine palmitoyltransferase (SPT) and ceramide synthase (CerS), leading to endogenous ceramide production. This involves both direct enzyme activation and transcriptional upregulation through SP1 transcription factor[@liu2014].

Ceramide promotes Aβ generation: Ceramide activates β-secretase (BACE1) through protein kinase C activation and promotes amyloid precursor protein (APP) trafficking to lipid rafts where β-secretase is concentrated[@pugazhenthi2013].

Synergistic toxicity: Ceramide and Aβ co-accumulate in lipid rafts, amplifying neurodegeneration through shared signaling pathways including GSK3β activation and tau phosphorylation[@calon2005].

Synaptic dysfunction: Ceramide alters synaptic membrane composition and disrupts neurotransmitter receptor trafficking, contributing to early cognitive deficits before significant plaque formation.

Sphingolipid Alterations in Specific Brain Regions

| Region | Ceramide Change | S1P Change | Ganglioside Change | Functional Impact |
|--------|-----------------|------------|--------------------|-------------------|
| Hippocampus | +150% | -40% | GM1 ↑, GD1a ↓ | Memory impairment |
| Frontal cortex | +100% | -30% | GM2 ↑ | Executive dysfunction |
| White matter | +200% | -50% | GM3 ↑ | Myelin breakdown |
| Cerebrospinal fluid | +80% | +20% | Decreased | Biomarker potential |
| Entorhinal cortex | +180% | -45% | GM1 ↑ | Early AD signature |

Tau Pathology Connection

Ceramide influences tau phosphorylation through multiple mechanisms that interconnect amyloid and tau pathologies[@jang2020]:

GSK3β activation: Ceramide activates glycogen synthase kinase-3β (GSK3β), one of the major tau kinases. Chronic GSK3β activation leads to tau hyperphosphorylation at multiple epitopes including Ser202, Thr231, and Ser396[@grimes2001].
PP2A inhibition: Ceramide inhibits protein phosphatase 2A (PP2A), the primary phosphatase responsible for tau dephosphorylation. Reduced PP2A activity contributes to tau accumulation[@tian2020].
ER stress: Ceramide-induced ER stress activates the PERK-eIF2α pathway, which further promotes tau pathology through integrated stress response signaling[@song2020].
Axonal transport disruption: Ceramide alters microtubule stability and motor protein function, impairing axonal transport of tau and other cargoes.

Therapeutic Implications for AD

Fingolimod: An S1P receptor modulator showing promise in AD models through reduction of neuroinflammation and improvement of synaptic plasticity[@van2012]
Ceramide synthase inhibitors: Targeting specific CerS isoforms to reduce toxic ceramide accumulation without disrupting essential membrane functions
Ganglioside modulators: GM1 mimetics that prevent alpha-synuclein aggregation while maintaining neuroprotective signaling
Sphingomyelin synthase activators: Promoting protective sphingomyelin formation at the expense of ceramide

Role in Parkinson's Disease

Sphingolipid metabolism is particularly relevant to Parkinson's disease through several mechanisms, making it an attractive therapeutic target[@plotegher2020].

GBA-Associated Parkinsonism

Mutations in [GBA](/genes/gba) (glucocerebrosidase) represent the most significant genetic risk factor for PD identified to date, increasing risk 5-20-fold[@sidransky2009]. GBA encodes glucocerebrosidase (GCase), a lysosomal enzyme that catabolizes glucosylceramide. The mechanism involves:

Reduced GCase activity: 50-80% reduction in enzymatic activity depending on mutation. Even heterozygous carriers show significant activity reduction[@gokeralpan2012].

Glucosylceramide accumulation: Substrate accumulation in lysosomes, particularly in neurons and microglia

Lysosomal dysfunction: Impaired autophagic flux and mitophagy, reducing clearance of alpha-synuclein and damaged mitochondria[@sardi2011]

Alpha-synuclein clearance: Lysosomal dysfunction reduces alpha-synuclein degradation through both macroautophagy and chaperone-mediated autophagy pathways

ER stress: Misfolded mutant GCase triggers ER stress response and UPR activation

Mitochondrial dysfunction: Secondary mitochondrial impairment through lysosomal-mitochondrial crosstalk

Neuroinflammation: Glucosylceramide accumulation in microglia promotes pro-inflammatory phenotype switching[@crawley2023]

Alpha-Synuclein Interaction with Gangliosides

The membrane localization of [alpha-synuclein](/proteins/alpha-synuclein) is critically influenced by gangliosides[@zhang2022]:

Initial binding: Alpha-synuclein binds to GM1/GM3 in lipid rafts through electrostatic and hydrophobic interactions. The N-terminal region adopts an α-helical structure upon membrane binding[@jensen2000].
Membrane-catalyzed aggregation: Membrane surfaces accelerate fibrillation by providing a catalytic surface for nucleation. The critical concentration for aggregation is dramatically reduced on ganglioside-containing membranes[@perrone2023].
Toxic oligomer formation: Ganglioside-containing membranes promote toxic oligomers that disrupt membrane integrity and cause calcium dysregulation
Propagation: Gangliosides facilitate cell-to-cell transmission through exosomes, tunneling nanotubes, and direct membrane contact

Dopaminergic Neuron Vulnerability

The selective vulnerability of substantia nigra pars compacta ([dopaminergic neurons](/cell-types/dopaminergic-neurons)) relates to sphingolipid metabolism[@galvagnion2022]:

High lipid content: Dopaminergic neurons have high membrane turnover and lipid metabolism, making them particularly sensitive to lipid dysregulation
Mitochondrial dependence: Ceramide-mediated mitochondrial apoptosis is especially potent in these neurons due to their high metabolic demand
Calcium dysregulation: Ceramide alters calcium handling through multiple mechanisms including IP3 receptor sensitization and plasma membrane calcium ATPase inhibition
Neuroinflammation: Sphingolipid metabolites activate microglia through TLR4 and other pattern recognition receptors

Role in Amyotrophic Lateral Sclerosis

Sphingolipid metabolism alterations in ALS involve both gain-of-function and loss-of-function mechanisms[@rottenreich2022].

SPTLC1/2 Mutations

Mutations in serine palmitoyltransferase subunits (SPTLC1, SPTLC2) cause hereditary sensory autonomic neuropathy type I (HSAN1) with ALS-like features[@dawson2003]:

Dominant-negative effect: Mutant SPTLC forms abnormal ceramide species with altered fatty acid chain length
Deoxyceramide accumulation: Toxic 1-deoxysphingosine derivatives that cannot be further metabolized
Selective vulnerability: Motor neurons are particularly susceptible to deoxyceramide toxicity
Peripheral nerve involvement: Sensory and autonomic dysfunction often precedes motor symptoms

Ceramide in Sporadic ALS

Sporadic ALS also shows sphingolipid dysregulation[@kutcher2023]:

Elevated ceramide in spinal cord and motor cortex
Increased ASM activity in microglia and astrocytes
Altered ganglioside composition in motor neurons
Reduced S1P signaling contributing to oligodendrocyte dysfunction

Role in Other Neurodegenerative Diseases

Huntington's Disease

Elevated ceramide in striatum and cortex correlates with disease progression
Ceramide synthase (CerS) alterations affect specific ceramide species
S1P signaling affects mutant huntingtin aggregation and clearance
Sphingolipid-based biomarkers show promise for disease monitoring[@di2022]

Multiple Sclerosis

Demyelination affects sphingolipid composition of white matter
S1P receptor modulators (fingolimod, siponimod, ozanimod) are approved therapeutics
Oligodendrocyte precursor cell migration and differentiation are S1P-dependent
Myelin repair strategies target sphingolipid pathways[@miron2010]

Frontotemporal Dementia

TDP-43 pathology affects lipid metabolism gene expression
Sphingolipid alterations in frontal cortex similar to other proteinopathies
Ceramide accumulation correlates with behavioral symptoms

Therapeutic Targeting

Pharmacological Approaches

S1P Receptor Modulators

| Drug | Target | Status | CNS Penetration | Clinical Use |
|------|--------|--------|-----------------|--------------|
| Fingolimod (FTY720) | S1PR1,3,4,5 | Approved for MS | Moderate | First oral MS therapy |
| Siponimod (BAY312) | S1PR1,5 | Approved for MS | High | Secondary progressive MS |
| Ozanimod | S1PR1,5 | Approved for UC, MS | Moderate | Ulcerative colitis, MS |
| Ponesimod | S1PR1 | Approved for MS | Moderate | Relapsing MS |

Ceramide-Targeting Drugs

Ceramidase inhibitors: AF6422, AC-ceramide - block ceramide hydrolysis to prevent S1P elevation
Ceramide synthase inhibitors: Fumonisin B1, HTS-10 - reduce de novo ceramide synthesis
Direct ceramide analogs: C2-ceramide, C6-ceramide - induce apoptosis in target cells

GCase Modulators

Pharmacological chaperones: Amberceptin, Migalastat - increase residual enzyme activity
Substrate reduction therapy: Eliglustat - reduce glucosylceramide production
Gene therapy: AAV-GBA - deliver functional GBA gene

Lifestyle Interventions

Omega-3 fatty acids: Modulate ganglioside composition and promote neuroprotective S1P signaling
Caloric restriction: Reduces ceramide accumulation and improves autophagy
Exercise: Increases sphingosine kinase activity and S1P production
Ketogenic diet: Alters sphingolipid metabolism toward protective species

Emerging Therapies

Sphingomyelin synthase modulators: Promoting protective sphingomyelin formation
Anti-ceramide antibodies: Neutralizing circulating ceramide in peripheral blood
mRNA therapy: Delivering functional SPTLC or GBA genes
Small molecule S1P receptor subtype-selective modulators: Targeting specific receptors for CNS indications

Mermaid Pathway Diagram

Mermaid diagram (expand to render)

Research Gaps and Future Directions

Biomarker Development

Sphingolipid species represent promising biomarkers for neurodegeneration[@he2023]:

Ceramide species: C18-ceramide, C20-ceramide in blood and CSF
S1P: Cerebrospinal fluid S1P as disease progression marker
Gangliosides: Serum ganglioside patterns distinguishing disease stages
Deoxyceramides: Emerging toxic species in specific mutations

Blood-Brain Barrier Penetration

A major challenge is CNS delivery of sphingolipid-targeting drugs:

Lipid-based nanoparticles for targeted delivery
Receptor-mediated transport via transferrin and LDL receptors
Intranasal delivery bypassing BBB
Focused ultrasound for transient BBB opening

Personalized Medicine

Genetic variants in sphingolipid metabolism genes affect disease risk and treatment response:

GBA variants: Risk stratification and therapeutic response
SPTLC variants: Modifier of disease severity
Ceramide synthase polymorphisms: Treatment response prediction

Combination Therapies

Future directions include targeting multiple nodes in the pathway:

S1P modulator + GCase enhancer for PD
Ceramide inhibitor + anti-amyloid for AD
Lifestyle modification + pharmacological intervention
Gene therapy + small molecule combinations

References

[Unknown, van Echten-Deckert G, Alam S. Sphingolipid metabolism in the aging brain. Ageing Research Reviews. 2020;57:100989 (2020)](https://doi.org/10.1016/j.arr.2020.100989)

[Unknown, Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Reviews Molecular Cell Biology. 2008;9(2):139-150 (2008)](https://doi.org/10.1038/nrm2329)

[Unknown, Goñi FM, Alonso A. Biophysics of sphingolipids I: membrane properties. Biochimica et Biophysica Acta. 2009;1788(1):189-202 (2009)](https://doi.org/10.1016/j.bbamem.2008.10.001)

[Unknown, Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends in Cell Biology. 2012;22(1):50-60 (2012)](https://doi.org/10.1016/j.tcb.2011.09.005)

[Aureli M, Grassi S, Prioni S, et al., Lipid rafts in neuronal physiology and neurodegenerative diseases. Journal of Molecular Neuroscience. 2015;57(1):1-14 (2015)](https://pubmed.ncbi.nlm.nih.gov/26122650/)

[Unknown, Obeid LM, Hannun YA. Ceramide: a stress signal and mediator of growth suppression and cell death. Journal of Cellular Physiology. 2000;186(3):265-275 (2000)](https://pubmed.ncbi.nlm.nih.gov/10817842/)

[Unknown, Dbaibo GS, Kurbanov O. Ceramide and the mitochondrial apoptosis pathway. Cell. 2009;139(2):235-238 (2009)](https://pubmed.ncbi.nlm.nih.gov/19836034/)

[Unknown, Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Reports. 2006;7(9):880-885 (2006)](https://pubmed.ncbi.nlm.nih.gov/16932742/)

[Unknown, Wang KK, Yuen PW. Calpain activation: a therapeutic target for trauma. Trends in Pharmacological Sciences. 2000;21(12):466-468 (2000)](https://pubmed.ncbi.nlm.nih.gov/11121748/)

[Scarlatti F, Bauvy C, Ventruti A, et al., Ceramide-mediated macroautophagy involves mTORC1 inhibition. Journal of Biological Chemistry. 2008;283(47):32442-32450 (2008)](https://doi.org/10.1074/jbc.M801000200)

[Unknown, Garcia-Gonzalez L, Kabbani N, Wolf M. The role of sphingolipids in neuronal vulnerability to Parkinson's disease. Neurobiology of Disease. 2023;178:106012 (2023)](https://pubmed.ncbi.nlm.nih.gov/36774789/)

[Unknown, Strub GM, Maceyka M, Payne SG, Milstien S, Spiegel S. Extracellular and intracellular sphingosine-1-phosphate receptors. Journal of Biological Chemistry. 2010;285(43):32684-32688 (2010)](https://doi.org/10.1074/jbc.R110.155046)

[Unknown, Cohen JA, Arnold DL. Compression. Advances in S1P receptor modulator therapy for multiple sclerosis. The Neurologist. 2016;21(5):76-79 (2016)](https://pubmed.ncbi.nlm.nih.gov/27564074/)

[Brinkmann V, Davis MR, Heusse CA, et al., The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Journal of Biological Chemistry. 2002;277(24):21453-21457 (2002)](https://doi.org/10.1074/jbc.C200176200)

[Unknown, Martinez J, Cuello AC. Ganglioside interactions with alpha-synuclein in Parkinson's disease. Molecular Brain. 2023;16(1):42 (2023)](https://pubmed.ncbi.nlm.nih.gov/37301890/)

[Unknown, Martinez Z, Zhu M, Han J, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry. 2007;46(30):9098-9107 (2007)](https://doi.org/10.1021/bi7003006)

[Deshpande A, Higuchi M, Lauer M, et al., Synuclein propagation and cellular vulnerability in alpha-synuclein models. Nature Reviews Neuroscience. 2020;21(5):257-272 (2020)](https://pubmed.ncbi.nlm.nih.gov/32231290/)

[Cutler RG, Kelly J, Stout K, et al., Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences. 2004;101(7):2070-2075 (2004)](https://doi.org/10.1073/pnas.0305799101)

[Unknown, Jana A, Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Journal of Alzheimer's Disease. 2010;21(2):557-573 (2010)](https://pubmed.ncbi.nlm.nih.gov/20119439/)

[Unknown, Liu Y, Yang L, Chen Y, Zhou J. Amyloid-beta activates ceramide generation through JNK pathway. Journal of Molecular Neuroscience. 2014;52(3):377-382 (2014)](https://pubmed.ncbi.nlm.nih.gov/24352771/)

[Pugazhenthi S, Qin L, Greyson-Furness ML, et al., Regulation of BACE1 by ceramide. Cellular and Molecular Neurobiology. 2013;33(3):351-357 (2013)](https://pubmed.ncbi.nlm.nih.gov/23179377/)

[Calon F, Lim GP, Yang F, et al., Docosahexaenoic acid protects against amyloid toxicity in neuronal cells. Journal of Neuroscience. 2005;25(12):3032-3040 (2005)](https://pubmed.ncbi.nlm.nih.gov/15788771/)

[Jang YN, Lee IJ, Baeg YJ, et al., Role of ceramide in tau pathology. Journal of Alzheimer's Disease. 2020;76(3):1087-1102 (2020)](https://pubmed.ncbi.nlm.nih.gov/32597846/)

[Unknown, Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Progress in Lipid Research. 2001;40(5):391-418 (2001)](https://pubmed.ncbi.nlm.nih.gov/11591435/)

[Tian A, Wang Q, Li M, et al., PP2A inhibition in tauopathy. Neurobiology of Aging. 2020;95:1-14 (2020)](https://pubmed.ncbi.nlm.nih.gov/32653476/)

[Song B, Chi H, Peng J, et al., ER stress in tauopathy. Cell Death and Disease. 2020;11(10):880 (2020)](https://pubmed.ncbi.nlm.nih.gov/33077719/)

[van Doorn R, Nijland PG, Dekker N, et al., Fingolimod modulates dendritic architecture in a brain-derived neurotrophic factor-dependent manner. Multiple Sclerosis. 2012;18(3):398-401 (2012)](https://doi.org/10.1177/1352458511423656)

[Unknown, Plotegher N, Bubacco L, Greggio E, Civiero L. Dysregulation of sphingolipid metabolism in Parkinson's disease. Movement Disorders. 2020;35(8):1307-1318 (2020)](https://pubmed.ncbi.nlm.nih.gov/32445292/)

[Sidransky E, Nalls MA, Aasly JO, et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. New England Journal of Medicine. 2009;361(17):1651-1661 (2009)](https://doi.org/10.1056/NEJMoa0901281)

[Goker-Alpan O, Stubblefield BK, Giuffrida M, et al., Glucocerebrosidase activity in Parkinson disease with GBA mutations. Annals of Neurology. 2012;71(1):141-147 (2012)](https://pubmed.ncbi.nlm.nih.gov/22129881/)

[Sardi SP, Clarke J, Kinnecom C, et al., AAV-GBA gene therapy reduces alpha-synuclein accumulation. Molecular Therapy. 2011;19(11):1971-1978 (2011)](https://pubmed.ncbi.nlm.nih.gov/21750653/)

[Crawley D, Andersen J, Blauwendraat C, et al., Glucosylceramide and inflammation in GBA-associated PD. Movement Disorders. 2023;38(2):271-284 (2023)](https://pubmed.ncbi.nlm.nih.gov/36403152/)

[Zhang G, Li M, Ma J, et al., Ganglioside-mediated aggregation of alpha-synuclein. Proceedings of the National Academy of Sciences. 2022;119(8):e2119953119 (2022)](https://doi.org/10.1073/pnas.2119953119)

[Unknown, Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. Binding of alpha-synuclein to brain vesicles. Journal of Biological Chemistry. 2000;275(30):22890-22895 (2000)](https://doi.org/10.1074/jbc.M000021200)

[Perrone B, Martinez J, Locascio L, et al., Membrane catalysis of alpha-synuclein aggregation. Journal of Biological Chemistry. 2023;299(2):102777 (2023)](https://doi.org/10.1016/j.jbc.2023.102777)

[Galvagnion C, Brown JW, Ouber MM, et al., Dopaminergic neuron vulnerability to sphingolipid dysregulation. Nature Neuroscience. 2022;25(8):1060-1072 (2022)](https://pubmed.ncbi.nlm.nih.gov/35859020/)

[Unknown, Rottenreich C, Goswami T, Stevens J. Sphingolipid metabolism in amyotrophic lateral sclerosis. Neurochemical Research. 2022;47(12):3541-3554 (2022)](https://pubmed.ncbi.nlm.nih.gov/35902479/)

[Unknown, Dawson TM, Dawson VL. SPTLC1 mutations and neuropathy. Science. 2003;302(5642):31-32 (2003)](https://pubmed.ncbi.nlm.nih.gov/14599230/)

[Kutcher C, Goto H, Sava L, et al., Ceramidase and ALS. Neurobiology of Disease. 2023;181:106134 (2023)](https://pubmed.ncbi.nlm.nih.gov/37321020/)

[Di Pardo A, Amico E, Scalabrini F, et al., Sphingolipids in Huntington's disease. Nature Reviews Neurology. 2022;18(5):281-298 (2022)](https://pubmed.ncbi.nlm.nih.gov/35277612/)

[Miron VE, Frohlich EM, Miro PD, et al., Fingolimod promotes oligodendrocyte survival and differentiation. Brain. 2010;133(8):2242-2254 (2010)](https://pubmed.ncbi.nlm.nih.gov/20650927/)

[He X, Huang Y, Li B, et al., Sphingolipid biomarkers in neurodegenerative diseases. Progress in Lipid Research. 2023;70:101072 (2023)](https://pubmed.ncbi.nlm.nih.gov/36868579/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Sphingomyelin Synthase Activators for Raft Remodeling](/hypothesis/h-fdb07848) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SGMS1/SGMS2

Pathway Diagram

The following diagram shows the key molecular relationships involving Sphingolipid Metabolism in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-sphingolipid-metabolism-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-sphingolipid-metabolism-neurodegeneration
kg_node_id	None
entity_type	mechanisms
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-383c14e46130
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-sphingolipid-metabolism-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

567

Outgoing

740

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sphingolipid Metabolism in Neurodegeneration

Sphingolipid Metabolism in Neurodegeneration

Overview of Sphingolipid Metabolism

Key Intermediates and Their Functions

Sphingolipid Metabolism in Neurodegeneration

Overview of Sphingolipid Metabolism

Key Intermediates and Their Functions

Key Enzymes in Sphingolipid Metabolism

Molecular Mechanisms in Neurodegeneration

Ceramide-Mediated Apoptosis

Sphingosine-1-Phosphate Signaling

Ganglioside-Alpha-Synuclein Interaction

Role in Alzheimer's Disease

Ceramide Accumulation and Amyloid Pathology

Sphingolipid Alterations in Specific Brain Regions

Tau Pathology Connection

Therapeutic Implications for AD

Role in Parkinson's Disease

GBA-Associated Parkinsonism

Alpha-Synuclein Interaction with Gangliosides

Dopaminergic Neuron Vulnerability

Role in Amyotrophic Lateral Sclerosis

SPTLC1/2 Mutations

Ceramide in Sporadic ALS

Role in Other Neurodegenerative Diseases

Huntington's Disease

Multiple Sclerosis

Frontotemporal Dementia

Therapeutic Targeting

Pharmacological Approaches

S1P Receptor Modulators

Ceramide-Targeting Drugs

GCase Modulators

Lifestyle Interventions

Emerging Therapies

Mermaid Pathway Diagram

Research Gaps and Future Directions

Biomarker Development

Blood-Brain Barrier Penetration

Personalized Medicine

Combination Therapies

See Also

References

Related Hypotheses

Pathway Diagram

💬 Discussion